Key Takeaways
- Addiction Recovery Care (ARC) was Kentucky’s largest substance use disorder treatment provider, operating more than 30 facilities at its peak in summer 2024. By January 2026, it had shrunk to 14 locations, was enmeshed in multiple federal lawsuits, and its founder’s sworn declaration stated that just $3.8 million remained across all company accounts.
- An FBI Medicaid fraud investigation, begun in summer 2024, triggered ARC’s rapid contraction. The company has not been criminally charged and the investigation remains open, but the investigation alone caused facility closures, staff layoffs, and a chain of financial consequences that unfolded over eighteen months.
- A planned acquisition by Ethema Health Corporation, announced October 2025, collapsed by December 31, 2025. Ethema’s CEO publicly stated ARC’s founder planned to use sale proceeds to satisfy a $27.7 million DOJ settlement obligation. Leon later said the founder may have misspoken. The $27.7 million figure has since appeared repeatedly in court filings.
- ARC sold approximately $8 million in employee retention tax credits to Angelica Capital Trust to raise liquidity ahead of the Ethema closing. When the deal collapsed, ARC kept the IRS-disbursed funds rather than forwarding them to Angelica, triggering a federal lawsuit. A second lender, Clear Cove Partners, then emerged claiming ARC had sold the same receivables to two different parties.
- On January 23, 2026, a federal judge froze $4.7 million of ARC’s remaining funds. ARC’s founder and other owners were ordered to appear at a contempt hearing after Angelica alleged the company had violated a temporary restraining order.
- The case exposes structural vulnerabilities specific to Medicaid-dependent SUD providers: thin operating margins, heavy regulatory exposure, and an acquisition ecosystem in which troubled providers cycle through purchasers with their own complicated histories. Ethema, the company that nearly acquired ARC, had previously purchased facilities from Edgewater, another Kentucky SUD provider that settled a DOJ Medicaid fraud investigation for $2.2 million in 2024.
In the summer of 2024, Addiction Recovery Care was the largest provider of substance use disorder treatment in Kentucky, operating more than 30 facilities across the state and serving as a cornerstone of the region’s response to an opioid epidemic that has killed tens of thousands. By January 2026, the company had been reduced to 14 locations, was fighting off multiple lawsuits in federal court in Manhattan, had watched its planned acquisition collapse, and was running out of money. A sworn declaration by its founder stated that just $3.8 million remained across all company accounts as of mid-January. Days later, a federal judge froze $4.7 million of the company’s funds.
The trajectory from dominance to distress has been rapid and, in its particulars, unusually revealing. The case of Addiction Recovery Care, known in Kentucky as ARC, is not merely the story of one troubled provider. It is a case study in the fragility of the substance use disorder treatment industry: an industry built on thin margins, heavy Medicaid dependence, and a regulatory environment that can turn a federal investigation into an existential crisis long before any charges are filed.
An FBI Medicaid Fraud Investigation Triggers ARC’s Rapid Decline
The first public indication of trouble came in the summer of 2024, when the FBI began actively seeking information about ARC’s operations in connection with a potential Medicaid fraud investigation. The company has not been criminally charged, and the case remains open. But the investigation’s effects were immediate and cascading. By September 2025, ARC had closed five additional facilities and laid off dozens of employees, shrinking its footprint to 14 locations from a peak of more than 30.
The financial distress accelerated. In October 2025, ARC announced what appeared to be a lifeline: Ethema Health Corporation, a Florida-based behavioral health and SUD provider operating in Kentucky under the brand ARIA Kentucky, signed a letter of intent to purchase ARC’s Kentucky facilities. Ethema’s CEO, Shawn Leon, told Kentucky Public Radio that ARC’s founder, Tim Robinson, would use proceeds from the sale to make a payment to the U.S. Department of Justice as part of a pending settlement over the Medicaid fraud investigation. Leon later said Robinson may have misspoken. But the statement introduced a figure that would reappear in subsequent court filings: a $27.7 million settlement obligation with the DOJ.
The Ethema Acquisition Collapse That Ended ARC’s Last Rescue Plan
The Ethema acquisition was supposed to be a rescue. Together, the two companies’ combined operating revenue could have topped $100 million, and Leon spoke publicly about consolidating services and expanding the number of addiction treatment beds in Kentucky. The plan was for ARC to be absorbed into an Ethema subsidiary, rebranded, and given what Leon described as a fresh start.
But by December 31, 2025, both parties had mutually terminated the agreement. Neither company offered a detailed explanation. Ethema said in a press release that it would pursue other growth opportunities. ARC’s spokesperson told Behavioral Health Business that the company would not comment on pending litigation.
The collapse of the deal triggered a chain of financial consequences that are now playing out in the U.S. District Court for the Southern District of New York.
Employee Retention Tax Credits, Competing Lenders, and a $3.8 Million Bank Balance
At the center of ARC’s legal troubles are a set of federal employee retention tax credits that the company sold to raise cash. According to court filings, ARC entered into a contract with Angelica Capital Trust in which the firm agreed to purchase approximately $8 million worth of IRS tax credits that ARC expected to receive. The purpose, the filings state, was for ARC to obtain liquidity quickly in order to make the company more attractive to Ethema as a potential buyer.
The IRS disbursed the funds to ARC on December 2, 2025. But ARC did not forward the money to Angelica. Instead, according to the lawsuit Angelica filed on January 12, 2026, ARC told the firm that the Ethema deal had failed and that it was attempting to negotiate a sale with a new buyer. Angelica’s filing described the situation bluntly: ARC was keeping the money because it was in desperate straits.
A second lender, Clear Cove Partners, subsequently emerged with its own claim to the same tax credits, alleging that ARC had sold the same receivables to two different parties. The competing claims have further complicated ARC’s financial position.
A sworn declaration by Tim Robinson, filed on January 20, 2026, offered a stark picture. As of January 13, there was a total of $3,817,171.03 across all of ARC’s bank accounts. The company, Robinson stated, was paying only those operating expenses absolutely necessary to continue operations: food for patients, medications, lab supplies, and utilities. The declaration warned that forcing ARC to pay the $8 million to Angelica would halt day-to-day operations.
On January 23, a federal judge ordered $4.7 million of ARC’s remaining funds frozen. Robinson and other ARC owners were ordered to appear at a contempt hearing after Angelica alleged the company had violated the terms of a temporary restraining order issued earlier that month.
The $27.7 Million DOJ Settlement That Haunts Every Court Filing
The DOJ has not publicly confirmed a settlement or any other resolution related to ARC. But the $27.7 million figure appears in multiple court filings. Angelica’s lawsuit claims the DOJ settlement was partially predicated on the sale of the company to Ethema, and that the sale of the employee retention credits to Angelica was part of the company’s financial representation to federal prosecutors. A contract document filed in the proceedings includes language linking the settlement terms to the completion of the acquisition.
ARC’s legal counsel, Jessica Burke, wrote in a December 30 email included in the court record that ARC was within 30 days of closing a deal with another buyer. The email warned Angelica that if the closing did not occur, ARC would be forced to seek debtor protection or reorganization, an outcome Burke described as being in neither party’s interest. Robinson’s January 20 declaration echoed the assertion, stating that a pending financial transaction was expected to close in or around the end of January 2026 or shortly thereafter.
What the Collapse of Kentucky’s Largest SUD Provider Reveals About Medicaid-Dependent Treatment
The collapse of Addiction Recovery Care is instructive beyond its particulars. The company’s trajectory illustrates a set of structural vulnerabilities that run through the SUD treatment industry. Medicaid-dependent providers operate on margins that leave almost no room for legal or regulatory disruption. A federal investigation, even one that has not produced charges, can trigger a death spiral of facility closures, staff layoffs, and financial distress that makes the very resolution regulators are seeking harder to achieve. Patients, meanwhile, lose access to treatment in a state where opioid overdose deaths remain among the highest in the country. The same dynamic has played out across behavioral health sectors where consolidation and thin margins intersect, producing instability that outlasts any individual provider’s story.
The case also raises uncomfortable questions about the acquisition ecosystem in behavioral health. Ethema Health, the company that nearly purchased ARC, had previously acquired facilities from Edgewater, another Kentucky SUD provider that had been under FBI investigation for fraudulent billing and settled with the DOJ for $2.2 million in 2024. The pattern, troubled providers cycling through acquisitions by other firms with their own complicated histories, is not unique to Kentucky.
For the patients who remain in ARC’s 14 remaining facilities, the immediate concern is continuity of care. Robinson’s declaration states that the company continues to pay for food, medications, and utilities. Whether a new buyer materializes, and whether that buyer can assume the obligations ARC has accumulated, will determine whether Kentucky’s largest addiction treatment provider survives in any form. The broader question, whether the regulatory and financial architecture of SUD treatment in America is adequate to prevent this kind of collapse from recurring, remains, for now, unanswered.
Frequently Asked Questions
What is Addiction Recovery Care, and what happened to it?
Addiction Recovery Care (ARC) was Kentucky’s largest substance use disorder treatment provider, operating more than 30 facilities at its peak in summer 2024. In summer 2024, the FBI began seeking information about the company’s operations in connection with a potential Medicaid fraud investigation. ARC has not been criminally charged and the investigation remains open. But the investigation triggered a rapid contraction: by September 2025, the company had closed facilities and laid off employees, shrinking to 14 locations. A planned acquisition by Ethema Health Corporation collapsed on December 31, 2025. By mid-January 2026, ARC’s founder declared in a federal court filing that just $3.8 million remained across all company accounts, and a federal judge subsequently froze $4.7 million of the company’s remaining funds pending a contempt hearing.
What is the $27.7 million DOJ settlement referenced in the ARC court filings?
The DOJ has not publicly confirmed a settlement or any resolution related to ARC’s Medicaid fraud investigation. However, the figure of $27.7 million appears repeatedly in filings from the federal lawsuit Angelica Capital Trust brought against ARC in January 2026. Angelica’s lawsuit alleges the DOJ settlement was partially predicated on ARC’s sale to Ethema Health, and that the employee retention tax credit transaction with Angelica was part of ARC’s financial representation to federal prosecutors. Ethema’s CEO told Kentucky Public Radio that ARC’s founder planned to use sale proceeds to pay the DOJ; Leon later said the founder may have misspoken. ARC founder Tim Robinson’s sworn January 2026 declaration references a pending financial transaction that he said was expected to close by the end of January or shortly after, which would presumably address the DOJ obligation, but no such closing was publicly confirmed.
What are employee retention tax credits and how did they become the center of ARC’s legal dispute?
Employee retention tax credits (ERTCs) are federal tax credits available to businesses that retained employees during the COVID-19 pandemic. Companies with credits they were entitled to receive from the IRS could sell those credits to third-party buyers in exchange for immediate liquidity. According to court filings, ARC entered into a contract with Angelica Capital Trust to sell approximately $8 million in tax credits, with the purpose of raising cash quickly to strengthen its financial position ahead of the planned Ethema acquisition. The IRS disbursed the funds to ARC on December 2, 2025. When the Ethema deal collapsed on December 31, ARC did not forward the funds to Angelica, explaining that it needed the money to continue operations. A second lender, Clear Cove Partners, then emerged claiming it had also purchased the same receivables, raising allegations that ARC had sold the same asset twice. The dispute is now before the U.S. District Court for the Southern District of New York.
Why are Medicaid-dependent SUD providers particularly vulnerable to federal investigations?
Substance use disorder treatment providers in the U.S. are heavily dependent on Medicaid reimbursement, particularly in states like Kentucky where Medicaid expansion under the Affordable Care Act significantly expanded coverage for SUD services. That dependence creates a specific vulnerability: when federal investigators begin examining Medicaid billing practices, the investigation itself, even without charges or convictions, can trigger consequences that threaten the provider’s survival. Payers may delay or suspend payments pending the investigation’s resolution. Lenders may pull credit. Staff may leave for more stable employment. Potential buyers who might otherwise acquire the company factor legal exposure into their valuation. The result is a death spiral in which the investigation’s collateral effects can destroy a company’s viability before any legal finding is made. The SUD treatment sector’s fragmentation and thin margins mean most providers lack the financial reserves to withstand even a temporary disruption of this kind, let alone an eighteen-month investigation period.
What does the ARC collapse reveal about behavioral health M&A and the acquisition ecosystem?
The ARC case exposes a pattern in behavioral health mergers and acquisitions that is not unique to Kentucky: troubled providers cycling through acquisitions by other firms that themselves have complicated regulatory or legal histories. Ethema Health, which signed a letter of intent to purchase ARC in October 2025, had previously acquired facilities from Edgewater, another Kentucky SUD provider that settled a DOJ Medicaid fraud investigation for $2.2 million in 2024. This pattern raises questions about due diligence standards in behavioral health transactions, the role acquisitions play in resolving regulatory obligations, and whether distressed-asset buyers in this sector are equipped to address the clinical and compliance liabilities they absorb. The consolidation dynamics across behavioral health have accelerated in recent years, but ARC illustrates that rapid consolidation in a thin-margin, heavily regulated sector can create systemic fragility rather than resilience.
What happens to ARC patients if the company cannot find a buyer?
ARC’s founder Tim Robinson stated in his January 20, 2026, sworn declaration that the company was continuing to pay for food for patients, medications, lab supplies, and utilities. But with a federal judge having frozen $4.7 million of the company’s remaining funds and the company’s total bank balance at roughly $3.8 million as of mid-January, the financial runway is extremely limited. If no buyer materializes or a debt restructuring is not reached, ARC would likely be forced to seek bankruptcy protection or close remaining facilities. For patients in active treatment, a sudden closure would require emergency transfer to other providers in a state where addiction treatment capacity is already strained. Kentucky’s opioid overdose death rate remains among the highest in the country, and ARC’s remaining 14 facilities represent a substantial share of the state’s residential SUD treatment infrastructure.
